Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan to Import Pfizer’s Pediatric Vaccine Next Month, Inoculations to Begin in March: Minister
January 25, 2022
- MHLW Panel Backs Wholesaler Data Use to Monitor Vaccine Shortages in Public Programs
January 25, 2022
- Providing Info on Investigational Drugs on Company Websites Violates PMD Law: MHLW
January 25, 2022
- Lilly’s Retevmo Up for PAFSC Review for Thyroid Cancer on Feb. 4; Lenvima-Keytruda Combo on Agenda for RCC
January 24, 2022
- No Major Safety Concerns for COVID-19 Jabs: MHLW Panels
January 24, 2022
- Promote Both Pfizer/Moderna Vaccines for Boosters: Health Minister
January 24, 2022
- Veklury Allowed for Administration in Homebound Patients
January 24, 2022
- JPMA Calls for Data Consolidation under Medical Infrastructure Law: Govt Hearing
January 24, 2022
- MHLW Approves Lilly’s Migrane Drug Reyvow, Amgen’s KRAS Inhibitor and More
January 21, 2022
- Pfizer’s Comirnaty Bags Japan Approval for Ages 5-11; Actemra OK’ed for COVID-19
January 21, 2022
- Govt Panel Compiles Draft Proposal for Bill to Bolster Supply Chains for Drugs, Essential Resources
January 21, 2022
- Pfizer’s Comirnaty Clears Key Panel for Ages 5-11; Actemra Set for COVID-19 Nod
January 21, 2022
- Chuikyo OKs Revised NHI Pricing Rules for FY2022 Price Revision
January 20, 2022
- Macroeconomic Indexing Lacks Perspectives to Promote Innovation, Improve Care: MHLW Bureau Chief
January 20, 2022
- Japan to Beef Up Pharma Supply Chain through Economic Security Bill
January 19, 2022
- Re-Pricing to Hit 23 Drugs in April; Takecab, GLP-1s, Vyndaqel/Vynmac, and More
January 19, 2022
- LDP Lawmakers Want Specific Definitions for Emergency Approval Prerequisites
January 18, 2022
- Japan Aims to Make Pfizer COVID-19 Pills Available Next Month: PM
January 18, 2022
- MHLW Panel Positive for OTC Switch for 4 Drugs Including Xyzal, Cautious on Rozerem
January 18, 2022
- Difolta Label Updated to Alleviate ADRs by Using Folinate
January 18, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…